KVP Capital Advisors, LP
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$124.3M2026 Q3
Positions36
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.57.4%
What Changed This Quarter?
Top Holdings
PRAX
Praxis Precision Medicines
10.1%
WHWK
Whitehawk Therapeutics
6.6%
SLN
Silence Therapeutics
6.0%
PTGX
Protagonist Therapeutics
6.0%
MBX
MBX Biosciences
5.7%
ERAS
Erasca
5.4%
TRVI
Trevi Therapeutics
4.8%
TNGX
Tango Therapeutics
4.6%
New / Increased
4 new · 0 increased
SLNNEW
Silence Therapeutics
6.0%
VogenxNEW
Vogenx
1.6%
Adial Pharmac…NEW
Adial Pharmaceuticals
0.7%
YARWNEW
Yarrow Bioscience
0.2%
Reduced / Exited
1 reduced · 3 sold out
IRON
Disc Medicine
2.3%
-24.9%
AXSMEXIT
Axsome Therapeutics
2.2%
SRRKEXIT
Scholar Rock
1.8%
Vyne Therapeu…EXIT
Vyne Therapeutics
0.2%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.